UNSPSC 51352206: Diethylstilbestrol dipalmitate

This classification denotes a non-steroidal estrogen with the molecular formula C50H80O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86291XW83U, chemically known as hexadecanoic acid, (1,2-diethyl-1,2-ethenediyl)di-4,1-phenylene ester, (e)-, but more generally known as diethylstilbestrol dipalmitate, which bears US NIH Compound Identifier 3032511. European Medicines Agency schedules diethylstilbestrol dipalmitate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07112MIG.

Most nations, for tariff purposes, schedule diethylstilbestrol dipalmitate under HS 29072900. SMILES: CCCCCCCCCCCCCCCC(=O)OC1CCC(CC1)/C(=C(\CC)/C2CCC(CC2)OC(=O)CCCCCCCCCCCCCCC)/CC.

UNSPSC 51352206 Diethylstilbestrol dipalmitate is a Commodity code for a specific pharmaceutical product, but the recent state and local procurement activity tagged under this code involves broad-based generic multi-source pharmaceuticals and over-the-counter (OTC) products rather than this single active ingredient. State and local agencies procure through cooperative purchasing agreements that consolidate demand across multiple jurisdictions and establish vendor contracts with pricing that flows through authorized wholesale distributors. The work includes manufacturer qualification, product registration with National Drug Codes and associated identifiers, pricing negotiation across multiple format options, and compliance with FDA requirements, current Good Manufacturing Practices (cGMP), and the Drug Supply Chain Security Act (DSCSA). Issuing bodies include state departments and state-administered cooperative purchasing alliances that aggregate demand on behalf of participating counties, cities, school districts, and other local entities within the purchasing group.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities, with an initial focus on Minnesota and Oregon. The solicitation requires vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain contractual relationships with at least two of the three, and demonstrate pricing flexibility through flat price, net price formats, or WAC-minus pricing structures. Evaluation is weighted heavily toward price competitiveness (75 percent), with 10 percent for fixed pricing, 5 percent for administrative fee format compliance, 5 percent for EDI capability, and 5 percent for agreement to a 3 percent administrative fee. Proposals were due March 26, 2026, with optional two-year contract terms for new vendors and amendments aligning with existing expiration dates through June 30, 2028 for incumbents. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and patient safety needs.